Australia approves Paxlovid and Lagevrio for COVID-19

The TGA also added that both drugs should be started as soon as possible after confirmation of the diagnosis. Story Coronavirus pandemic of a new type that spread from China The Therapeutic Goods Authority of Australia (TGA) has approved the use of Paxlovid by Pfizer and Lagevrio by Merck Sharp & Dohme for the treatment of COVID-19 in adults, reports TASS. Recall that the first domestic direct-acting injection drug for the treatment of COVID-19 “Areplivir” was recently registered in Russia. Истoчник aif.ru Also, the head of the Ministry of Health of the Russian Federation, Mikhail Murashko told about the development of a domestic drug that allows interrupting the development of COVID-19 at the initial stage. Paxlovid is designed both for the prevention of coronavirus infection and for the treatment of patients with high and medium risk of a severe course of the disease. “None of the approved drugs is intended to be used as a substitute for vaccination against COVID-19,” — clarified the regulator.